Associated products

The link you have chosen leads to a site maintained by a third party over whom Bracco Imaging has no control. As such, Bracco Imaging makes no representation as to the accuracy or any other aspect of the information on this site. The clinical use of Bracco Imaging Products in these pages may not be consistent with the approved indications.

The information on this site is not country specific and may contain information that is outside the approved indication where you practice.

By checking this box and clicking the submit button of this page, I certify that I am a U.S. healthcare professional, and give permission for Bracco Diagnostics Inc., or parties acting on its behalf, to contact me with information regarding Bracco Diagnostics Inc. products and solutions, invitations to events and seminars, industry updates and other notifications. I understand that the information I provide will not be given to anyone outside Bracco Diagnostics Inc. except for the agents or representatives processing this request.

As with all injectable contrast agents, the possibility of severe reactions should be borne in mind, regardless of the patient's pre-existing medical history. As with any other iodinated contrast media, caution must be exercised in patients with severely impaired renal function, combined renal and hepatic disease, combined renal and cardiac disease, severe thyrotoxicosis, myelomatosis, or anuria, particularly when large doses are administered.

*The ISOVUE Imaging Bulk Package is for use with an automated contrast injector or a contrast management system approved or cleared for use with it.

Please see full Prescribing Information for ISOVUE (Iopamidol Injection) by clicking here.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

ISOVUE and ISOVUE-M are currently manufactured for Bracco Diagnostics Inc. at two locations: BIPSO GmbH, Singen (Germany) and Patheon Italia S.p.A., Ferentino, (Italy).

ISOVUE and ISOVUE-M are registered trademarks of Bracco Diagnostics Inc.

IMPORTANT SAFETY INFORMATION:
ISOVUE (Iopamidol Injection) IS NOT FOR INTRATHECAL USE. Iopamidol Injection is available as ISOVUE-M® (Iopamidol Injection) for intrathecal administration.

Caution must be exercised in patients with severely impaired renal function, those with combined renal and hepatic disease, or anuria, particularly when larger and repeat doses are administered. Radiopaque diagnostic contrast agents are potentially hazardous in patients with multiple myeloma or other paraproteinemia, particularly in those with therapeutically resistant anuria. Caution should be exercised in hydrating patients with underlying conditions that may be worsened by fluid overload, such as congestive heart failure. Diabetic nephropathy may predispose to acute renal impairment following intravascular contrast media administration. Acute renal impairment following contrast media administration may precipitate lactic acidosis in patients who are taking biguanides. Preparatory dehydration is dangerous and may contribute to acute renal failure in patients with advanced vascular disease, diabetic patients, and in susceptible nondiabetic patients (often elderly with preexisting renal disease). Patients should be well hydrated prior to and following iopamidol administration.

The possibility of a reaction, including serious, life-threatening, fatal, anaphylactoid or cardiovascular reactions, should always be considered. Patients at increased risk include those with a history of a previous reaction to a contrast medium, patients with a known sensitivity to iodine per se, and patients with a known clinical hypersensitivity (bronchial asthma, hay fever, and food allergies).

*The ISOVUE Imaging Bulk Package is for use with an automated contrast injector or a contrast management system approved or cleared for use with it.

Please see full Prescribing Information for ISOVUE Imaging Bulk Package by clicking here.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

ISOVUE and ISOVUE-M are currently manufactured for Bracco Diagnostics Inc. at two locations: BIPSO GmbH, Singen (Germany) and Patheon Italia S.p.A., Ferentino (Italy).

ISOVUE and ISOVUE-M are registered trademarks of Bracco Diagnostics Inc.

As with all injectable contrast agents, the possibility of severe reactions should be borne in mind, regardless of the patient's pre-existing medical history. As with any other iodinated contrast media, caution must be exercised in patients with severely impaired renal function, combined renal and hepatic disease, combined renal and cardiac disease, severe thyrotoxicosis, myelomatosis, or anuria, particularly when large doses are administered.

*The ISOVUE Imaging Bulk Package is for use with an automated contrast injector or a contrast management system approved or cleared for use with it.

Please see full Prescribing Information for ISOVUE (Iopamidol Injection) by clicking here.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

ISOVUE and ISOVUE-M are currently manufactured for Bracco Diagnostics Inc. at two locations: BIPSO GmbH, Singen (Germany) and Patheon Italia S.p.A., Ferentino, (Italy).

ISOVUE and ISOVUE-M are registered trademarks of Bracco Diagnostics Inc.

IMPORTANT SAFETY INFORMATION:
ISOVUE (Iopamidol Injection) IS NOT FOR INTRATHECAL USE. Iopamidol Injection is available as ISOVUE-M® (Iopamidol Injection) for intrathecal administration.

Caution must be exercised in patients with severely impaired renal function, those with combined renal and hepatic disease, or anuria, particularly when larger and repeat doses are administered. Radiopaque diagnostic contrast agents are potentially hazardous in patients with multiple myeloma or other paraproteinemia, particularly in those with therapeutically resistant anuria. Caution should be exercised in hydrating patients with underlying conditions that may be worsened by fluid overload, such as congestive heart failure. Diabetic nephropathy may predispose to acute renal impairment following intravascular contrast media administration. Acute renal impairment following contrast media administration may precipitate lactic acidosis in patients who are taking biguanides. Preparatory dehydration is dangerous and may contribute to acute renal failure in patients with advanced vascular disease, diabetic patients, and in susceptible nondiabetic patients (often elderly with preexisting renal disease). Patients should be well hydrated prior to and following iopamidol administration.

The possibility of a reaction, including serious, life-threatening, fatal, anaphylactoid or cardiovascular reactions, should always be considered. Patients at increased risk include those with a history of a previous reaction to a contrast medium, patients with a known sensitivity to iodine per se, and patients with a known clinical hypersensitivity (bronchial asthma, hay fever, and food allergies).

*The ISOVUE Imaging Bulk Package is for use with an automated contrast injector or a contrast management system approved or cleared for use with it.

Please see full Prescribing Information for ISOVUE Imaging Bulk Package by clicking here.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

ISOVUE and ISOVUE-M are currently manufactured for Bracco Diagnostics Inc. at two locations: BIPSO GmbH, Singen (Germany) and Patheon Italia S.p.A., Ferentino (Italy).

ISOVUE and ISOVUE-M are registered trademarks of Bracco Diagnostics Inc.

RESP product logo

Find your local rep

Contacts

Indications and Usage

Indications and Usage:VoLumen® Barium Sulfate Suspension (0.1% w/v, 0.1% w/w) is indicated for use in computed tomography to opacify the GI tract.

IMPORTANT SAFETY INFORMATION: For Oral Administration. This product should not be used in patients with known or suspected perforation of the GI tract, known obstruction of the GI tract, high risk of aspiration, or hypersensitivity to barium sulfate products. Rarely, severe allergic reactions of anaphylactoid nature have been reported following administration of barium sulfate contrast agents.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.